From Lawsuit to Love Story: How Novo Nordisk and Hims Buried the Hatchet

Under the new deal, Hims & Hers can sell FDA-approved Wegovy (both injectable and oral) and Ozempic injections at Novo's self-pay prices. We're talking the complete dose lineup: five Wegovy injection strengths, four oral tablet doses, and three Ozempic strengths. It's the whole menu.

In return, Hims agreed to stop marketing compounded GLP-1 drugs to the general public. The company can still offer compounded semaglutide, but only in rare cases where a clinician documents that the branded product won't work for a specific patient. No more mass advertising of cheap knockoffs.

Novo dropped the lawsuit, though it kept the right to refile if Hims strays from the agreement. Think of it as a legal leash: you're free, but we're holding the other end.

Why Novo Needed This Deal Too

It's tempting to read this as Hims surrendering. But Novo had its own reasons to negotiate. The GLP-1 market is enormous (Wegovy and Ozempic are two of the best-selling drugs on Earth), and a huge chunk of potential patients pay cash because their insurance won't cover weight-loss treatment.

Novo executive Mike Doustdar told Reuters that "authentic products are now priced similarly to the compounded alternatives." That's the whole game. By pricing branded Wegovy and Ozempic competitively for self-pay patients and distributing through telehealth platforms, Novo can capture demand that was flowing to compounders.

Hims & Hers has roughly 2.5 million subscribers. That's a massive consumer funnel Novo can tap without building its own direct-to-consumer infrastructure from scratch. Other telehealth platforms like Ro and LifeMD already distribute Wegovy through NovoCare, Novo's self-pay pharmacy program. Adding Hims gives Novo the biggest DTC partner in the space.

Eli Lilly is running a similar playbook with its GLP-1 drugs (Mounjaro and Zepbound), distributing through LillyDirect and telehealth partners. The race to own the direct-to-consumer GLP-1 channel is on, and Novo clearly decided that suing Hims was less valuable than enlisting them.

Wall Street Lost Its Mind (in a Good Way)

The market reaction was dramatic. Hims shares surged more than 50% in pre-market trading when reports of the deal first surfaced. Multiple firms upgraded the stock from Hold to Buy.

Leerink analyst Michael Cherny called the announcement "both unexpected and a clear positive for HIMS' stock," noting that investors had been braced for a long, expensive legal fight. Barclays flagged a key trade-off: Hims will earn significantly lower margins selling branded Wegovy than it did on $49 compounded pills, but removing the legal and regulatory risk makes the business far more durable.

Citi analyst Daniel Grosslight put a number on the challenge. He estimated Hims would need to sell 70% more branded subscriptions to offset the revenue lost from ending mass compounded sales. That's a steep hill to climb, but it beats the alternative of a patent trial against one of the world's largest drugmakers.

Novo's stock barely moved. One new distribution partner is a rounding error on the quarterly earnings call. The strategic value (controlling how GLP-1s reach cash-pay patients) matters more than any near-term revenue bump.

The Bigger Picture: Compounding Is Dying

This deal didn't happen in a vacuum. The FDA has been systematically closing the door on mass-produced compounded GLP-1s. After declaring the semaglutide shortage resolved, the agency gave 503A pharmacies (state-licensed, patient-specific) until April 22, 2025 and 503B outsourcing facilities (bulk producers) until May 22, 2025 to wind down copy-cat production.

In April 2026, the FDA went even further, proposing a rule that would permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk compounding list. If finalized, even a future shortage wouldn't automatically let outsourcing facilities start mass-producing GLP-1 copies again.

The regulatory message is unambiguous: if you want semaglutide, get the real thing.

What Comes Next

Hims plans to educate its weight-loss customers about the expanded FDA-approved options and help existing compounded patients transition to branded products. The companies have described this as a "long-term" collaboration with ambitions to bring future Novo products onto the Hims platform as they launch.

For patients, the practical effect is straightforward. You can now get a telehealth consultation on Hims, receive a prescription from a licensed provider, and have real Wegovy or Ozempic shipped to your door at Novo's self-pay prices. No insurance required, no compounding pharmacy in the middle.

It's a remarkable turn. Twelve months ago, these two companies were in open warfare. Now they're business partners with a shared incentive: sell as many branded GLP-1 prescriptions as possible to millions of cash-pay Americans who want access to weight-loss drugs without navigating the insurance maze.

From lawsuit to love story. Pharma is weird like that.